EUVIMEDEUVIMED entdecken
Multizentrische Studie

First evidence of olaparib maintenance therapy in patients with newly diagnosed homologous recombination deficient positive/BRCA wild-type ovarian cancer: real-world multicenter study

Jing Li, Youguo Chen, Mian He, Xiaoxiang Chen, Hao Wen, Yu Kang, Kaijiang Liu, Ge Lou, Xipeng Wang, Qinglian Wen, Li Wang, Zhongqiu Lin

Frontiers of Medicine · 2024-12 · 18 (6) · 1026-1034

DOI: 10.1007/s11684-024-1083-5 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Frontiers of Medicine, online erschienen am 06.11.2024. Verfasst von Jing Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynaecological Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China. Hauptthemen laut MEDLINE: Phthalazines, Piperazines, Ovarian Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhthalazinesPiperazinesOvarian NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsHumansFemaleMiddle AgedRetrospective StudiesAdultAgedChinaMaintenance ChemotherapyBRCA2 ProteinAntineoplastic AgentsProgression-Free SurvivalBRCA1 Protein

Stichwörter der Autor:innen

adverse eventsmaintenance therapyolaparibovarian cancerprogression-free survival

Substanzen

olaparibPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsBRCA2 ProteinAntineoplastic AgentsBRCA1 Protein

Autor:innen und Institutionen

  • Department of Gynaecological Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China.
  • Department of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
  • Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, China.
  • Department of Gynecological Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, 211166, China.
  • Department of Gynecological Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
  • Department of Gynecological Oncology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, 215311, China.

Zitieren

APA

Li, J., Chen, Y., He, M., Chen, X., Wen, H., Kang, Y., Liu, K., Lou, G., Wang, X., Wen, Q., Wang, L., & Lin, Z. (2024). First evidence of olaparib maintenance therapy in patients with newly diagnosed homologous recombination deficient positive/BRCA wild-type ovarian cancer: real-world multicenter study. Frontiers of Medicine, 18(6), 1026-1034. https://doi.org/10.1007/s11684-024-1083-5

Vancouver

Li J, Chen Y, He M, Chen X, Wen H, Kang Y, et al. First evidence of olaparib maintenance therapy in patients with newly diagnosed homologous recombination deficient positive/BRCA wild-type ovarian cancer: real-world multicenter study. Frontiers of Medicine. 2024;18(6):1026-1034. doi:10.1007/s11684-024-1083-5

BibTeX
@article{Li2024,
  author = {Li, Jing and Chen, Youguo and He, Mian and Chen, Xiaoxiang and Wen, Hao and Kang, Yu and Liu, Kaijiang and Lou, Ge and Wang, Xipeng and Wen, Qinglian and Wang, Li and Lin, Zhongqiu},
  title = {First evidence of olaparib maintenance therapy in patients with newly diagnosed homologous recombination deficient positive/BRCA wild-type ovarian cancer: real-world multicenter study},
  journal = {Frontiers of Medicine},
  year = {2024},
  volume = {18},
  number = {6},
  pages = {1026--1034},
  doi = {10.1007/s11684-024-1083-5}
}
Kostenlos starten →